Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9308977 | 0.95 | AGTR1 (0.66) | AGTR1 | |
| SCHEMBL9309816 | 0.93 | AGTR1 (0.63) | AGTR1 | |
| SCHEMBL9308916 | 0.91 | AGTR1 (0.61) | AGTR1 | |
| SCHEMBL22800020 | 0.91 | AGTR1 (0.63) | AGTR1 | |
| SCHEMBL9309944 | 0.90 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL9309293 | 0.90 | AGTR1 (0.59) | AGTR1 | |
| SCHEMBL9308067 | 0.88 | AGTR1 (0.57) | AGTR1 | |
| SCHEMBL9310969 | 0.87 | AGTR1 (0.57) | AGTR1 | |
| Ripisartan SCHEMBL12465608 | 0.85 | AGTR1 (1.00) | AGTR1 | |
| SCHEMBL9308909 | 0.84 | AGTR1 (0.54) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | UNIVERSITY OF LOWA RESEARCH FOUNDATION (US) | 2024-03-19 | — | — | US | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | claimed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | claimed |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-04 | — | — | US | claimed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | claimed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | claimed |
| EP-1085887-A4 | NOVEL ANGIOTENSIN RECEPTOR MODULATORS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | claimed |
| EP-1085887-A2 | NOVEL ANGIOTENSIN RECEPTOR MODULATORS AND THEIR USES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| EP-0759754-A4 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1999063930-A2 | NOVEL ANGIOTENSIN RECEPTOR MODULATORS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5830909-A | DIETETICS | AMERICAN CYANAMID COMPANY (US) | 1998-11-03 | — | — | US | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 5/4885 |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | AGTR2, AGTR1, MUSK | AGTR1 2/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | AGTR1 25/4885 |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | AGTR1 25/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 4/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 4/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.